alexa [Multi-center randomized clinical study on Shenqi-fuzheng injection combined with chemotherapy in the treatment for lung cancer].
Pharmaceutical Sciences

Pharmaceutical Sciences

Journal of Bioequivalence & Bioavailability

Author(s): Lin HS, Li DR

Abstract Share this page

Abstract OBJECTIVE: To investigate the effect of Shenqi-fuzheng injection combined with chemotherapy on the quality of life in lung cancer patient. METHODS: 232 pathologically confirmed nonsmall cell lung cancer patients were enrolled into this multi-center randomized trial. Of these 232 patients, 116 cases were treated with chemotherapy alone (chemotherapy group), another 116 with chemotherapy combined with Shenqi-fuzheng injection produced by Lizhu Company (Shenqi-fuzheng group). Life quality of these patients were evaluated using the QOL scale of European Organization for Research on Treatment of Cancer (QLQ-C30) and the functional living index-cancer. RESULTS: Compared with chemotherapy group, Life quality and symptoms were improved in the Shenqi-fuzheng group, which including lassitude, deficient in breath, pain, fullness in chest and hypochondrium, excessive phlegm, cough, complexion whiteness. Response rate to chemotherapy was also improved. No AE and SAE were observed in the Shenqi-fuzheng group. CONCLUSION: Shenqi-fuzheng injection combined with chemotherapy is safe and effective in the treatment for non-small cell lung cancer.
This article was published in Zhonghua Zhong Liu Za Zhi and referenced in Journal of Bioequivalence & Bioavailability

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version